Immune-Onc Therapeutics has dosed the first subject in the Phase Ib/II trial of IO-108 plus Roche’s atezolizumab and bevacizumab as a potential first-line treatment for hepatocellular carcinoma ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of ... Genentech’s Avastin (bevacizumab), The trial met its primary ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

In the study, the therapy was assessed in combination with the standard-of-care atezolizumab and bevacizumab ... including subjects with programmed cell death ligand 1 (PD-L1) negative disease ...

Jobevne is approved for multiple cancer types, including colorectal, non-small cell lung ... oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line ...

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

The care of patients with metastatic renal-cell carcinoma (mRCC ... The efficacy of single-agent bevacizumab in the first-line setting merits evaluation, and the relative toxicity profiles ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...